Literature DB >> 9822265

Study of anti-neutrophil cytoplasmic antibodies in patients with thromboangiitis obliterans (Buerger's disease).

K S Halacheva1, I M Manolova, D P Petkov, A P Andreev.   

Abstract

The presence of antineutrophil cytoplasmic antibodies (ANCA) and their specificity to myeloperoxidase, lactoferrin and elastase were studied in 27 patients with thromboangiitis obliterans (Buerger's disease), including nine in mild stage of the disease (group I) and 18 in active or severe stage (group II). Serum samples were investigated for ANCA prevalence by indirect immunofluorescent technique and fixed neutrophil ELISA; the reactivity to myeloperoxidase, lactoferrin and elastase was measured by ELISA. ANCA were found in 55.5% (15/27) of the patients by indirect immunofluorescence and in 59.25% (16/27) by fixed neutrophil ELISA. A highly significant positive association was observed between the values obtained by the two methods. Only six of 15 ANCA-positive sera reacted with myeloperoxidase and four of 15 with lactoferrin. One ANCA-negative serum reacted with elastase. Antimyeloperoxidase, antilactoferrin and antielastase autoantibodies were found only in the severe group. There was statistically significant difference in the frequency of ANCA in sera of patients with thromboangiitis obliterans versus control sera. ANCA were predominantly found in group II (66.7%; 12/18) compared to group I (33.3%; 3/9) and the levels of antimyeloperoxidase, antilactoferrin and antielastase antibodies correlated with disease severity. Therefore, detection of ANCA can be a helpful serological test for the diagnosis of thromboangiitis obliterans.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9822265

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  3 in total

Review 1.  Clinical utility of testing for antineutrophil cytoplasmic antibodies.

Authors:  D Vassilopoulos; G S Hoffman
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

2.  Successful treatment of thromboangiitis obliterans (Buerger's disease) with immunoadsorption: results of a pilot study.

Authors:  Gert Baumann; Verena Stangl; Peter Klein-Weigel; Karl Stangl; Michael Laule; Kathrin Enke-Melzer
Journal:  Clin Res Cardiol       Date:  2011-03-05       Impact factor: 5.460

Review 3.  Buerger's disease: providing integrated care.

Authors:  Peter Klein-Weigel; Theresa Sophie Volz; Leonora Zange; Jutta Richter
Journal:  J Multidiscip Healthc       Date:  2016-10-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.